Ryan Winstead

Dr. Ryan Winstead

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Transplantation
Verified
Journal Article
Closed access
CICarlo J. Iasella
Carlo J. Iasella
RWRyan Winstead
Ryan Winstead
CMCody A. Moore
Cody A. Moore
BJBruce A. Johnson
Bruce A. Johnson
AFAyelet T. Feinberg
Ayelet T. Feinberg
CEChristopher R. Ensor
Christopher R. Ensor
Traditional immunosuppressive regimens (ISR) used in lung transplantation rely on calcineurin inhibitors (CNI) that occasionally cause severe adverse reactions necessitating discontinuation. Belatacept is a novel costimulation antagonist approved for use in renal transplantation which lacks data in lung transplantation. This series aims to describe the response to belatacept ISR in 11 lung transplantation recipients after CNI failure. Single center, retrospective medical record review of adult lung transplant recipients (LTR) before and after conversion to belatacept-based ISR. Patients were evaluated at fixed time points before and after belatacept initiation. Primary outcome was incidence of acute cellular rejection (ACR). Secondary outcomes included incidence of infection, Chronic Lung Allograft Dysfunction (CLAD) progression, death, change in mean arterial pressure (MAP) and estimated glomerular filtration rate (eGFR). Eleven LTRs received belatacept with a mean of 246 (91-1064) days of follow-up after conversion. Four were changed to belatacept for thrombotic thrombocytopenic purpura; 3 for posterior reversible encephalopathy syndrome; 2 for recurrent ACR; 1 for CLAD; and 1 for renal-sparing. ACR was not different before and after belatacpet (p=0.17). Mean eGFR was significantly higher postbelatacept (32.53 vs 45.26, p=0.04). Mean incidence of infections (24.4% vs 16.0%, p=0.55), and MAP (97.5 vs 92.1 p=0.38), were not different. Progression of CLAD occurred in 2 patients. At the end of follow-up, 7/11 patients were alive. Belatacept-based ISR appear to produce reasonable results in LTRs who fail CNI-based ISR. Larger prospective trials appear warranted in lung transplantation.

13 September 2020 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
CSChelsey Chenxi Song
Chelsey Chenxi Song
ABAndrew Brown
Andrew Brown
RWRyan Winstead
Ryan Winstead
IYIdris Yakubu
Idris Yakubu
MDMoses Demehin
Moses Demehin
GGGaurav Gupta
Gaurav Gupta
There is a paucity of data on the use of SGLT2 inhibitors on outcomes in kidney transplant recipients. There may be concern in initiating these agents, especially within the first year post‐transplant when renal function is more labile and immunosuppression more intense, due to a presumed high risk of urinary infections and acute kidney injury. This is a retrospective study on 50 kidney transplant recipients, half of whom were started on therapy within the first year of transplant. Over a follow‐up period of 6 months, overall patients had a statistically significant improvement in weight by −2.95 kg [SD 3.54, P = <.0001 (CI: 3.53, 1.50)] as well as hypomagnesemia 0.13 [SD 1.73, P = .0004 (CI: 0.06, 0.20)]. Overall insulin usage declined by −3.7 units [SD 22.8, P = .17]. 14% of patients had at least one urinary tract infection although this rate is not different (~20%) than that reported historically in this high‐risk population.

20 January 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
RWRyan Winstead
Ryan Winstead
DKDhiren Kumar
Dhiren Kumar
ABAndrew Brown
Andrew Brown
IYIdris Yakubu
Idris Yakubu
CSChelsey Song
Chelsey Song
GGGaurav Gupta
Gaurav Gupta

28 January 2020 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
RWRyan Winstead
Ryan Winstead
MDMoses Demehin
Moses Demehin
IYIdris Yakubu
Idris Yakubu
CSChelsey Song
Chelsey Song
ABAndrew Brown
Andrew Brown
GGGaurav Gupta
Gaurav Gupta

3 June 2019 in Progress in Transplantation
Verified
Journal Article
Closed access
PDF file
RWRyan Winstead
Ryan Winstead
GWGeorgina Waldman
Georgina Waldman
EAElizabeth B. Autry
Elizabeth B. Autry
RERickey A. Evans
Rickey A. Evans
ASAric Schadler
Aric Schadler
MGMegan E. Goetz
Megan E. Goetz
Introduction: Since the largest study on extensively drug-resistant organisms and lung transplantation in patients with cystic fibrosis, there have been innovations and advancements in the treatment of Pseudomonas aeruginosa. Research Question: What differences exist for patients with cystic fibrosis with a history of extensively drug-resistant infections who undergo lung transplantation despite treatment advances with antimicrobial therapy? Study Design: Two-center, retrospective, cohort study conducted in 44 patients with cystic fibrosis chronically infected with extensively drug-resistant organisms who received a lung transplant from January 2008 through August 2016. Patients in the resistant cohort were chronically infected with pan-resistant P aeruginosa, polymyxin-sensitive only, or sensitive to 2 antibiotic classes (polymyxin plus one other); remaining patients with more susceptible P aeruginosa or no P aeruginosa remained in the control cohort. The primary outcome is a composite of patient survival, retransplantation, chronic lung allograft dysfunction, and acute rejection 12 months posttransplant. Categorical variables were analyzed using χ2 testing. The independent samples t test was utilized for continuous variables. Results: There was no difference in the primary outcome (40% vs 37%, P = .831). Differences between patient survival (84% vs 95%, P = .487), the incidence of acute rejection (20% vs 33%, P = .323), and the incidence of chronic lung allograft rejection (12% vs 5%, P = .441) were not different between groups. Discussion: Recipients chronically infected with an extensively resistant P aeruginosa had similar outcomes compared to those infected with more sensitive organisms.

1 April 2019 in Critical Care Nurse
Verified
Journal Article
Closed access
PDF file
ASAdam Sieg
Adam Sieg
KPKomal Pandya
Komal Pandya
RWRyan Winstead
Ryan Winstead
RERickey Evans
Rickey Evans
Extracorporeal membrane oxygenation has become more widely used in recent years. Although this technology has proven to be lifesaving, it is not devoid of complications contributing to significant morbidity and mortality. Nurses who care for patients receiving extracorporeal membrane oxygenation should further their understanding of changes in medication profiles due to complex interactions with the extracorporeal membrane oxygenation circuitry. The aim of this comprehensive review is to give nurses a better understanding of analgesic, sedative, anti-infective, and anticoagulation medications that are frequently used to treat patients receiving extracorporeal membrane oxygenation.